FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: Single institutional analysis

European Journal of Haematology

Volumn 86, Issue 3, 2011, Pages 272-273

  Tashiro, Haruko ^a   Shirasaki, Ryosuke ^a   Oka, Yoko ^a   Sugao, Toshihiko ^a   Mizutani Noguchi, Mitsuho ^a   Yamamoto, Tadashi ^a   Akiyama, Nobu ^a   Kawasugi, Kazuo ^a   Shirafuji, Naoki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; STEROID;

BONE MARROW CELL; CENTRAL NERVOUS SYSTEM; GENE DUPLICATION; HUMAN; INTERNAL TANDEM DUPLICATION; LETTER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK;

ADOLESCENT; ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECURRENCE; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 79951662913     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01559.x     Document Type: Letter

References (9)

1. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005;19:1345-9.
2. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
3. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003;17:1454-63.
4. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43.
5. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res 2010;34:831-6.
6. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, Vandenberghe EA, Winship PR, Reilly JT. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000;111:190-5.
7. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007;110:59-66.
8. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008;111:2527-37.
9. Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 2005;130:196-202.